Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia

Jaehyuk Choi, Francine Foss*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity. Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalYale Journal of Biology and Medicine
Volume79
Issue number3-4
StatePublished - Dec 1 2006

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory materials
T-Cell Leukemia
Transplants
Pediatrics
T-cells
Stem Cell Transplantation
Stem cells
Nucleosides
Skin
Bone Marrow
Recurrence
clofarabine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{9f307e8a6c764e06a1aa0b30359c8802,
title = "Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia",
abstract = "Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity. Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.",
author = "Jaehyuk Choi and Francine Foss",
year = "2006",
month = "12",
day = "1",
language = "English (US)",
volume = "79",
pages = "169--172",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "3-4",

}

Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. / Choi, Jaehyuk; Foss, Francine.

In: Yale Journal of Biology and Medicine, Vol. 79, No. 3-4, 01.12.2006, p. 169-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia

AU - Choi, Jaehyuk

AU - Foss, Francine

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity. Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.

AB - Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity. Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.

UR - http://www.scopus.com/inward/record.url?scp=38549143381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549143381&partnerID=8YFLogxK

M3 - Article

C2 - 17940627

AN - SCOPUS:38549143381

VL - 79

SP - 169

EP - 172

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 3-4

ER -